Bluebird bio Inc (BLUE)

NASDAQ
Currency in USD
4.9800
+1.6700(+50.45%)
Closed·
Pre Market
4.9600-0.0200(-0.40%)
·
BLUE Scorecard
Full Analysis
Operates with a significant debt burden
Unusual trading volume
Fair Value
Day's Range
4.95004.9900
52 wk Range
3.200028.6000
Key Statistics
Edit
Prev. Close
4.98
Open
4.97
Day's Range
4.95-4.99
52 wk Range
3.2-28.6
Volume
9.43M
Average Volume (3m)
612.03K
1-Year Change
-76.73%
Book Value / Share
-3.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BLUE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.0000
Upside
+40.56%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Bluebird Company Profile

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Employees
248

Bluebird bio Inc SWOT Analysis


Gene Therapy Pionee
Explore bluebird bio's innovative treatments for severe genetic diseases, including its lead product Lyfgenia for sickle cell disease
Financial Tightrope
Delve into bluebird's financial challenges, with a limited runway extending into Q1 2025 and efforts to reach cash flow break-even by H2 2025
Market Potential
Analyst price targets range from $2 to $40, reflecting diverse views on bluebird's growth prospects in the expanding gene therapy market
Launch Execution
Learn about bluebird's progress in patient starts across treatments and the critical importance of successful product launches for future success
Read full SWOT analysis

Bluebird bio Inc Earnings Call Summary for Q3/2024

  • Patient starts more than doubled to 57 in Q3; Q4 revenue expected to rebound to $25M+ despite Q3 decline to $10.6M
  • Cash flow breakeven targeted for H2 2025, contingent on securing additional funding; 20% reduction in operating expenses planned
  • Over 50% of U.S. states confirm coverage for LYFGENIA; manufacturing capacity to double by 2026 to meet demand
  • Reverse stock split proposed to regain NASDAQ compliance; shareholder meeting scheduled for December 4
  • Company managing cash gap anticipated in Q2 2025 through contract renegotiations and partnerships
Last Updated: 15-11-2024, 02:28 am
Read Full Transcript

Compare BLUE to Peers and Sector

Metrics to compare
BLUE
Peers
Sector
Relationship
P/E Ratio
−0.2x−2.1x−0.5x
PEG Ratio
−0.01−0.010.00
Price/Book
−1.5x1.2x2.6x
Price / LTM Sales
0.6x17.6x2.9x
Upside (Analyst Target)
61.3%557.4%51.4%
Fair Value Upside
Unlock7.6%9.5%Unlock

Analyst Ratings

1 Buy
4 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 7.0000
(+40.56% Upside)

Earnings

Latest Release
Feb 25, 2025
EPS / Forecast
-2.95 / -0.2944
Revenue / Forecast
38.52M / 26.06M
EPS Revisions
Last 90 days

FAQ

What Is the Bluebird (BLUE) Stock Price Today?

The Bluebird stock price today is 4.98.

What Stock Exchange Does Bluebird Trade On?

Bluebird is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Bluebird?

The stock symbol for Bluebird is "BLUE."

What Is the Bluebird Market Cap?

As of today, Bluebird market cap is 48.75M.

What Is Bluebird's Earnings Per Share (TTM)?

The Bluebird EPS (TTM) is -24.84.

From a Technical Analysis Perspective, Is BLUE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.